A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)

Liver Cancer Clinical Trial

— JET-HCC  

Official title:

A Phase III Randomized Double-blind, Placebo-controlled Trial of ARQ 197 in Subjects With c-MET Diagnostic-high Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Sorafenib Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02029157
• Other study ID #: ARQ 197-009
• Status: Completed
• Phase: Phase 3
• First received: December 27, 2013
• Last updated: October 6, 2017
• Start date: January 2014
• Est. completion date: August 2017

Study information

• Verified date: October 2017
• Source: Kyowa Hakko Kirin Co., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The present clinical trial is aiming to evaluate efficacy of ARQ 197 in patients with hepatocellular carcinoma (HCC), who were resistant or intolerable to one systemic chemotherapy regimen including sorafenib.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 386
• Est. completion date: August 2017
• Est. primary completion date: August 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Informed consent form

• =20 years old

• Inoperable HCC which is not eligible for locoregional therapy

• Diagnosed as c-Met high in tumor sample

• Radiographic progression is confirmed during or after systemic chemotherapy including sorafenib, or those who are intolerance to the chemotherapy.

• Eastern Cooperative Oncology Group Performance Status (ECOG PS) is 0 or 1

• Child-Pugh Class A

• Having measurable target lesions which are defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1,

• Negative pregnancy test results

• Adequate organ function

• Life expectancy of at least 12 weeks

Exclusion Criteria:

• More than 2 prior systemic chemotherapy.

• Prior therapy of c-Met inhibitor (including antibody)

• Any systemic therapy within =2 weeks prior to the randomization

• Locoregional therapy within =4 weeks prior to randomization.

• Major surgery within =4 weeks prior to the randomization

• Concurrent cancer within =5 years prior to the randomization

• History of cardiac diseases

• Active clinically serious infections defined as = Grade 3 according to Common Toxicity Criteria for Adverse Effects (CTCAE) 4.0

• Any psychological disorder affecting Informed Consent

• Diagnosis positive for anti-HIV antibody and/or anti-HTLV-1 antibody

• Blood or albumin transfusion within =14 days prior to the screening test

• Concurrent interferon therapy against Hepatitis B Virus (HBV)/ Hepatitis C Virus (HCV)

• Symptomatic brain metastases

• History of liver transplantation

• Inability to swallow oral medications

• Confirmed interstitial lung disease

• Pleural effusion and/or clinically significant ascites

• Pregnancy or breast-feeding

• Without consent to effective single or combined contraceptive methods

Related Conditions & MeSH terms

• Carcinoma, Hepatocellular
• Liver Cancer
• Liver Neoplasms

Intervention

Drug:
• ARQ197

• Placebo

Locations

Country	Name	City	State
Japan	Cancer Centers in Japan	Tokyo

Sponsors (1)

Lead Sponsor	Collaborator
Kyowa Hakko Kirin Co., Ltd

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival (PFS)	Progression-free survival will be compared between ARQ 197 group and Placebo group, to prove the efficacy of ARQ 197 in the population.	Estimated median of 8-12 weeks in PFS
Secondary	Overall survival	The date of the events was followed every three months after the end of the treatments of the study drug.	Estimated median of 24 weeks in overall survival